Answers are grounded in this paper and cite their sources.
The need to develop new antibiotics has been acknowledged as a clinical and public health priority for decades. To facilitate development of these critical medicines, the European Medicines Agency (EMA) provides several regulatory tools, including Scientific Advice (SA), the Priority Medicines (PRIME) scheme, and the Innovation Task Force (ITF). In the face of antimicrobial resistance, the question arises whether antibiotic developers are making effective use of the EMA's mechanisms to foster innovation. We chose publicly available EMA data from 2019-2023 to reflect on this question. During this period, EMA received 3,899 requests for innovation support. Of these, only 25 concerned antibiotics-representing less than 1% of all submissions and with 22 requests, SA was the most frequently used of the three available mechanisms. Even though the European framework provides several tools to support the development of new antibiotics, their uptake seems to be limited. Possible explanations include a small development pipeline, a possible mismatch between developers' needs and what regulators can provide, developers' preference for other jurisdictions, or challenges - particularly for small and medium-sized enterprises - that hinder full use of available tools. There seems to be a need to explore alternative regulatory support mechanisms for new antibiotics.
No takes yet. Share an insight, caveat, or question.
Opalska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: